📅 Save the Date: Join LifeSci Events and Disc Medicine for a virtual "Lunch with LifeSci" event on September 14th at 1:00 PM EDT! Disc Medicine is a clinical-stage #biotech company pioneering groundbreaking treatments for rare #BloodDiseases, erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), affecting 8,000 people in the US and Europe. 💡 What to Expect: 👉 Gain insights into Disc Medicine's transformative drug, Bitopertin, designed to alleviate extreme pain and skin damage triggered by sunlight exposure in EPP and XLP patients. 👉 Learn about Bitopertin's impressive 40% reduction in toxic byproduct PPIX, leading to enhanced quality of life and a 96% decrease in phototoxic reactions. 👉 Get a sneak peek into Disc Medicine's upcoming Phase 2 trial results for AURORA, promising even more progress. 👉 Explore Disc's second asset, DISC-0974, with potential applications in anemias associated with inflammatory diseases. 👉 Hear from John Quisel about the company's future and its exciting potential in the world of blood diseases. Reserve your seat: https://lnkd.in/e8vVmhB3 #LifeSciEvent #LifeSciences
LifeSci Search’s Post
More Relevant Posts
-
Can Understanding HO-1 in BACH1 Knockout Mice Help Treat Sepsis Better? Raghavan Pillai Raju, Medical College of Georgia at Augusta University, USA, will present a short oral contribution during #RedoxMedicine2024 elaborating on this topic. Dr. Raju will discuss the regulation of HO-1 in BACH1 knockout mice following sepsis. He will provide new insights into the regulatory mechanisms of HO-1 in response to sepsis, potentially informing new therapeutic strategies. Join us on June 27-28, 2024 at Fondation Biermans-Lapôtre, Paris, to learn more! 🔗 Selected Short Orals: https://lnkd.in/gypa9uFD. 🌐 More information: https://lnkd.in/dkNzFQZU. #RedoxMedicieSociety #RedoxMedicine2024 #biomarkers #redoxbiology #redox #antioxidants #innovation #oxidativestress #RedoxResearch
To view or add a comment, sign in
-
-
Not long to go until the PROMs Research Conference! Get in touch at https://bit.ly/4aPkmTV to arrange a chat with our team. We will be presenting the following posters at the event: Poster 1: Patient-reported outcome measures used in interventional studies of irritable bowel syndrome: a targeted review Poster 2: Outcomes and interventions in clinical studies investigating pharmacological therapies for the treatment of transthyretin amyloidosis: a targeted review https://bit.ly/4cb2sML
To view or add a comment, sign in
-
-
Endocrine Case Talks: Gastrinoma in Patients with MEN-1 Tuesday, February 20 10:00 AM ET Our speakers, Subramanian Kannan, MD; Kevin Moore, PhD; Kan Narasminhan, MD; and Julie Refardt, MD, will discuss how they address patients with Gastrinomas in Multiple Endocrine Neoplasia Type 1 (MEN-1): https://bit.ly/3OrSihb Learning Objectives: · To discuss the initial evaluation of gastrinoma · How is gastrinoma different in MEN-1 compared to sporadic gastrinoma? · To discuss the management of gastrinoma MEN-1 compared to sporadic gastrinoma
To view or add a comment, sign in
-
-
Today is the Alimentiv Translational Research Consortium (ATRC) Symposium! This years symposium is focused on all aspects of combination therapy for #IBD, with fantastic presentations planned about clinical efficacy and safety, pharmacology, translational medicine, and drug design and development. #translationalresearch #IBDresearch #precisionmedicine
Exciting News! ✨️ Alimentiv is thrilled to announce the 5th Alimentiv Translational Research Consortium (ATRC) Symposium: "The Next Frontier: Combination Therapy in Inflammatory Bowel Diseases (IBD)" happening this Friday, May 17th in Washington, DC. The symposium is a full-day educational Alimentiv event exploring the role of combination therapies in IBD and insights from other medical fields that have pioneered these approaches. This event will feature leading experts, including gastroenterologists, scientists, clinical pharmacologists, trialists, and industry sponsors. Alimentiv is proud to host this event and provide the opportunity for key opinion leaders to connect and advance the understanding of combination therapy in IBD! For more details, visit: https://lnkd.in/gedmHcGM #ATRC2024 #Alimentiv #PrecisionMedicine #IBD
To view or add a comment, sign in
-
-
Next week, Precisionary Instruments is thrilled to host Dr. Charlotte Dean, a world-renowned expert in lung slices - ‘mini-lungs’ for discovery and drug screening. Save your spot here: https://lnkd.in/eZmJGDY4 Dr. Dean's work with precision-cut lung slices (PCLS) is pivotal in studying lung injury and repair. These 'mini-lungs' are 3-D tissue pieces containing all resident lung cell types, offering a unique window into pulmonary research. Ever wondered about "precision-cut" tissue slices? How are they made and the research questions they unravel? Our latest article delves into creating healthy PCTS using the Compresstome vibratome, a must-read for those in pulmonary research and drug discovery. Check out our article here: https://lnkd.in/eeHfrGz6 Do you make precision-cut tissue slices for your research? Or are you planning to? We'd love to hear about your journey and experiences. Share your story with us and join the conversation! #PrecisionaryInstruments #compresstome #microtomes #vibratingmicrotomes #vibratomes #tissuesectioning #precisioncuttissuesslices #tissueslicing #laboratoryequipment #labsolutions
To view or add a comment, sign in
-
-
This month on the Lupus Forum we present the August Literature Highlights, this month discussing the top research and clinical data in #lupus therapy. Keep up to date on the latest data on #belimumab, #obexelimab, and #voclosporin. We also discuss recent research investigating #SGLT2 inhibitors and their renoprotective properties in #LN. Read on-the-go for free and stay up to date with the latest breakthroughs in #Lupus #SLE: https://lnkd.in/dDQbCijZ
To view or add a comment, sign in
-
🧬Chief Executive Officer | Board Member in Biotech, Advanced Therapies, Precision Medicine & Pharmaceuticals
Today I am thankful to our patients and colleagues for making this news possible ➡ robust clinical results in the 1st & 2nd cohorts of Sernova's Phase 1/2 T1D study with our cell pouch and ethically derived donor islet cells: 💥 5 of 6 patients in the first cohort of our Phase 1/2 study discontinued insulin therapy (they are insulin independent for between 6 months and 3.5+ years) following islet transplantation into the Cell Pouch and modest islet top-up via portal vein. 📉 All 6 patients achieved HbA1c values in the non-diabetic range (<6.5%). 🎯 In Cohort B, the first 6 of 7 planned patients have received the higher capacity 10-channel Cell Pouch and 5 patients have received a first islet transplant. 🥅 Stable fasting and stimulated serum C-peptide levels were observed following a single islet transplant into the 10-channel Cell Pouch in the first assessable Cohort B patient who subsequently achieved insulin independence with a modest portal vein top up. #T1D #CellTherapy #CellPouch #HbA1C #CPeptide #PatientCentricity #Biotechnology
Today, we announced new positive interim data from our ongoing Phase 1/2 clinical trial evaluating our novel #CellTherapy platform in people living with #Type1Diabetes (#T1D). The data was presented by Dr. Piotr Witkowski of UChicago Medicine in San Diego at the International Pancreas and Islet Transplant Association (IPITA)-International Xenotransplantation Association (IXA)-Cell Transplant and Regenerative Medicine Society (CTRMS) Joint Congress. Read our press release to learn more: https://brnw.ch/21wDUTH
To view or add a comment, sign in
-
-
1️⃣ Boston Scientific’s cardiac rhythm system hits pivotal trial goals. Boston Scientific, which presented the results at the Heart Rhythm Society meeting, expects to receive FDA approval for the system in 2025. 2️⃣ KT has introduced two new patches for diabetes care, featuring Pro Extreme adhesive to prevent CGM device detachment. 3️⃣ Click Therapeutics, Inc. has acquired assets from Better Therapeutics, potentially enhancing its portfolio in obesity, diabetes, and cardiometabolic diseases. 4️⃣ Indica Labs received FDA 510(k) clearance for its HALO AP Dx platform, which diagnoses surgical pathology slides. 5️⃣ Irmed’s PressureSafe device has shown to reduce pressure injury incidence by half in early detections. 6️⃣ Invizius completed a Phase I trial of its dialysis priming product, H-Guard, confirming its safety and efficacy. 7️⃣ Allez Health raised $60m led by Osang Healthcare to enhance its diabetes sensor technology. 8️⃣ MEDLINE INDUSTRIES LIMITED, LP introduced the TurboMist small-volume nebuliser, delivering medication more efficiently than standard nebulisers. #InsightswithSmarteeva #Medtech #complaintmanagement #Pharma #Smarteeva #biotech #medtechtrends #medtechindustry #medicaltechnology #technology #health #medicaldevicediagnostics #ai #mdr #recalls #complaints #mir #fda #cvr
Daily MedTech News with Smarteeva - 27th May
To view or add a comment, sign in
-
Chief Scientific Officer (MD-PhD) and biotech consultant with extensive research, education, and clinical background, team building, project management perfectionist, and fun embroidery enthusiast
How to make PCLS (precision-cut lung slices) is one of the most common questions I get. Read my latest blog article for tips and tricks. Respiratory research using PCLS is expanding, and I'm here for any help you may need.
Next week, Precisionary Instruments is thrilled to host Dr. Charlotte Dean, a world-renowned expert in lung slices - ‘mini-lungs’ for discovery and drug screening. Save your spot here: https://lnkd.in/eZmJGDY4 Dr. Dean's work with precision-cut lung slices (PCLS) is pivotal in studying lung injury and repair. These 'mini-lungs' are 3-D tissue pieces containing all resident lung cell types, offering a unique window into pulmonary research. Ever wondered about "precision-cut" tissue slices? How are they made and the research questions they unravel? Our latest article delves into creating healthy PCTS using the Compresstome vibratome, a must-read for those in pulmonary research and drug discovery. Check out our article here: https://lnkd.in/eeHfrGz6 Do you make precision-cut tissue slices for your research? Or are you planning to? We'd love to hear about your journey and experiences. Share your story with us and join the conversation! #PrecisionaryInstruments #compresstome #microtomes #vibratingmicrotomes #vibratomes #tissuesectioning #precisioncuttissuesslices #tissueslicing #laboratoryequipment #labsolutions
To view or add a comment, sign in
-
-
Click here for the full content: https://bit.ly/CT-807475 On Tuesday, October 31, #Adaptimmune updated its corporate deck and published 2 press releases announcing clinical updates from lete-cel (NY-ESO1 TCR-T) and afami-cel (MAGE-A4 SPEAR-T) to be presented at #CTOS2023 (November 1-4): • An interim analysis of the pivotal Ph2 IGNYTE-ESO (https://bit.ly/40pBU5r) trial evaluating lete-cel in r/r #synovialsarcoma (#SS) or myxoid/round cell liposarcoma (#MRCLS) (press release: https://bit.ly/3MqJRl6) • Interim results of Ph2 IGNYTE-ESO (https://bit.ly/40pBU5r) trial’s Substudy 1 (https://bit.ly/47jPl9E) evaluating lete-cel in treatment-naïve metastatic or unresectable SS or MRCLS patients • Data from Cohort 1 of afami-cel’s pivotal Ph2 SPEARHEAD-1 (https://bit.ly/3sswEl3) study in advanced SS (press release: https://bit.ly/3QnkSk2)
To view or add a comment, sign in
-